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1 INTRODUCTION 
1.1 General concepts about chronic rhinosinusitis 
 
Chronic rhinosinusitis is defined as a persistent symptomatic inflammation of the 
nasal and paranasal sinus mucosa, resulting from the interaction of multiple host 
and environmental factors.  
It is one of the most commonly reported diseases, being estimated as the second 
most prevalent chronic health condition, affecting 12.5% of the United States (US) 
population [Hamilos DL, 2011], and with an overall prevalence of 10.9% in 
Europe (ranging from 6.9 to 27.1% in different countries) [Hastan D at al., 2011].  
The burden of CRS to society is considerable and related to loss of productivity, 
office visits and medical expenses. Costs of medical and surgical care for CRS are 
estimated at about 8.6 billion dollars yearly in the US [Bhattacharyya N, 2011]. 
CRS has been shown to have a considerable negative impact on several aspects of 
quality of life [Birch DS et al., 2001] and has a greater impact on social functioning 
than chronic heart failure, angina or back pain [Gliklich RE et al., 1995; Suh JD et 
al., 2010]. 
CRS is clinically characterized by two or more symptoms, one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge 
(anterior/posterior nasal drip), and facial pain/pressure or reduction/loss of smell. 
Duration of symptoms has to be longer than 12 weeks, without complete 
resolution and with the possibility of periodical exacerbations [Meltzer EO et al., 
2004]. Nasal endoscopy and sinuses computed tomography are important for 
objective confirmation of the diagnosis, because of the false-positive and false-
negative rates arising from subjective criteria alone [Bhattacharyya N et al., 2010; 
Tomassen P et al., 2011].  
The widespread adoption of the term “rhinosinusitis” in preference to “sinusitis” 
indirectly supports the perspective that foreign material brought in through the 
airway, or perhaps from the nasopharynx, acts on the nasal mucosa first, with 
secondary effects direct and indirect on the sinus mucosa [Van Crombruggen K et 
al., 2010]. In a very small percentage of cases, such as dental and iatrogenic 
sinusitis, this pathway is reversed with processes in the sinus cavity leading to 
secondary inflammation. CRS may also, in rare cases, develop secondary to 
inflammatory processes intrinsic to the mucosa in the presumed absence of 
exogenous stimuli (e.g. Wegener’s granulomatosis, Churg-Strauss syndrome, 
Sarcoidosis). Lastly, CRS may occur in association with distinct host genetic 
factors (e.g. Cystic fibrosis) or systemic immunodeficiency [Fokkens WJ et al., 
2012, European Position Paper on Nasal Polyposis 2012, EPOS 2012].  
In the overwhelming majority of CRS cases, however, the aetiology and 
pathogenesis remain unclear. Idiopathic CRS has been typically divided into 2 
distinct phenotypes based on endoscopic findings, CRS with nasal polyps 
(CRSwNP) and CRS without nasal polyps (CRSsNP). CRSsNP is more tightly 
linked to mechanical obstruction of the ostio-meatal complex, while CRSwNP is 
generally attributed to a different inflammatory pattern of mucosal response 
[Leung RM et al., 2011], though these broad phenotypes do not provide full 
insight into the potential underlying pathophysiologic mechanisms of CRS and 
significant overlap between the two forms can exist.  
CRS is a complex inflammatory disease with several variants resulting mainly from 
dysfunctional host-environment interactions [Kern RC et al., 2008]. Different 
attempts to sub-classify CRS have been based mainly on clinical and 
histopathological features [Han JK, 2013; Stammberger H, 1999]. However, last 
trends support a deeper concept, that is, CRS consists of multiple biological 
subtypes, or “endotypes”, which are defined by distinct cellular and molecular 
mechanisms that might be identified by corresponding biomarkers and might 
differ in therapeutic responses [Akdis CA et al., 2013]. The characterisation of the 
heterogeneity of the underlying inflammatory process should then define the 
treatment plan. In other words, a specific kind of medication should be used for a 
specific kind of sinus inflammation. 
Medical therapy remains the cornerstone of CRS management and relies on 
combinations of antibiotics and oral or topical corticosteroids. The most recent 
medical treatment evidences and recommendations are reported in the last EPOS 
publication [Fokkens WJ et al., 2012] (Table 1; Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 - Treatment evidence and recommendations for adults with CRSsNP 
 
Therapy Level Grade Relevance 
steroid - topical Ia A yes 
nasal saline irrigation Ia A yes 
bacterial lysate (OM-85 BV) Ib A unclear 
oral antibiotic therapy short term < 4 
weeks 
II B during exacerbations 
oral antibiotic therapy long term ≥ 12 
weeks 
Ib C% 
yes, especially if IgE is not 
elevated 
steroid - oral IV C unclear 
mucolytics III C no 
proton pump inhibitors III D no 
decongestant oral / topical 
no data on single 
use 
D no 
allergen avoidance in allergic patients IV D yes 
oral antihistamine added in allergic 
patients 
no data D no 
herbal en probiotics no data D no 
immunotherapy no data D no 
probiotics Ib(-)§ A(-)° no 
antimycotics - topical Ib(-)§ A(-)° no 
antimycotics- systemic no data A(-)° no 
antibiotics - topical Ib(-)§ A(-)° no 
[Adapted from Fokkens WJ et al., 2012] 
 
Some of these studies also included patients with CRSwNP 
Acute exacerbations of CRS should be treated like acute rhinosinusitis 
§ Ib(-): Ib study with a negative outcome 
° A(-): grade A recommendation not to use 
% Level of evidence for macrolides in all patients with CRSsNP is Ib and strength of recommendation C, 
because two double-blind placebo controlled studies are contradictory; indication exist for better efficacy in 
CRSsNP patients with normal IgE (recommendation A). No RCTs exist for other antibiotics 
 
 
Table 2 - Treatment evidence and recommendations for adults with CRSwNP 
 
Therapy Level Grade Relevance 
topical steroids Ia A yes 
oral steroids Ia A yes 
oral antibiotic therapy short term 
< 4 weeks 
Ib and Ib(-)§ C# yes, small effect 
oral antibiotic therapy long term 
≥ 12 weeks 
III C 
yes, especially if IgE is not elevated, 
small effect 
capsaicin II C no 
proton pump inhibitors II C no 
aspirin desensitisation II C unclear 
furosemide III D no 
immunosuppressants IV D no 
nasal saline irrigation 
Ib, no data in 
single use 
D yes for symptomatic relief 
topical antibiotics no data D no 
anti IL-5 no data D unclear 
phytotherapy no data D no 
decongestant topical / oral 
no data in single 
use 
D no 
mucolytics no data D no 
oral antihistamine in allergic 
patients 
no data D no 
antimycotics - topical Ia(-)% A(-)° no 
antimycotics - systemic Ib(-)§ A(-)° no 
anti leukotrienes Ib(-)§ A(-)° no 
anti-IgE Ib(-)§ A(-)° no 
[Adapted from Fokkens WJ et al., 2012] 
 
Some of these studies also included patients with CRSsNP 
# Short term antibiotics show one positive and one negative study, therefore recommendation C 
§ Ib(-): Ib study with a negative outcome 
% Ia(-): Ia level of evidence that treatment is not effective 
° A(-): grade A recommendation not to use 
 
While a combination of these therapies is often effective in relieving symptoms, at 
least temporarily, they are rarely curative. In individuals failing to respond to 
medical therapy, surgical management is indicated and required, in the form of 
functional endoscopic sinus surgery (FESS), to remove diseased tissue and clear 
obstructed sinus drainage passages. FESS restores sinus health with complete or 
moderate relief of symptoms in about 90% of patients with recurrent or medically 
unresponsive CRS [Senior BA et al., 1998]. However, approximately in 20% of 
operated patients FESS fails [Hopkins C, Slack R. et al., 2009]. 
Those patients who complain persisting signs and symptoms of CRS, despite 
technically adequate endoscopic sinus surgery and well-leaned, specific, medical 
treatment, are considered to have a refractory/recalcitrant or difficult-to-treat CRS 
[Desrosiers M, 2004]. Many reports point out a role for more radical or extended 
surgeries in this group of patients, with the aim of reducing the high inflammatory 
load [Bassiouni A et al., 2012], combined with medical therapies, yet more 
determined by the individual experience of the single ENT centre/physician than 
by standardized clinical trial [Fokkens WJ, 2010]. A preoperative assessment giving 
a prognostic index of relapse based on clinical and cytological features has been 
proposed [Gelardi M, 2009]. Novel treatment strategies are about to spread 
[Desrosiers MY et al., 2008] but their efficacy is still unpredictable and needs to be 
proven on a large scale. The caractherization of precise endotypes will be of great 
help in tailoring these novel treatments. 
 
1.2 Aetiology and pathogenesis of chronic rhinosinusitis  
1.2.1 Predisposing factors 
 
The current diagnosis of CRS requires cardinal nasal symptoms and one objective 
sign of nasal inflammation. These rudimentary diagnostic criteria result in a 
heterogeneous group of “CRS” patients, making it difficult to investigate etiologies 
and outcomes [Orlandi RR et al., 2016].  
Several conditions have been recognized as predisposing or associated factors to 
CRS. All these conditions predispose CRS by different mechanisms, such as 
alterations of the epithelial respiratory structure and remodelling, deposition of 
extracellular matrix (ECM) proteins, damage to ciliated mechanical barrier, 
induction of inflammatory cytokines, impairment of the immunity system and 
obstruction of the nasal drainage and accumulation of secretions in the nose. 
Some of the more examined associations are listed below. 
1.2.1.1  Cil iary impairment 
The inability of the cilia to transport the viscous mucus causes obstruction of the 
sinus ostia, secondary ciliary malfunction and consequently CRS with recurrent 
polyposis and infections, mainly sustained by Pseudomonas aeruginosa [Fokkens 
WJ et al., 2012].  
1.2.1.2  Allergy  
It has been postulated that swelling of the nasal mucosa in allergic rhinitis at the 
site of the sinus ostia may compromise ventilation and even obstruct sinus ostia, 
leading to mucus retention and infection [Fokkens W et al. 2007].  
1.2.1.3  Asthma  
Bronchial asthma is considered a comorbid condition of CRS, as strongly 
suggested by a recent large-scale European survey, reporting an association of 
CRS, in the absence of nasal allergies, with late-onset asthma [Jarvis D et al., 2012].  
1.2.1.4  Aspir in sensi t iv i ty  
The presence of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) 
hypersensitivity in a patient with CRSwNP is associated with a particularly 
persistent and treatment-resistant form of the disease, coexisting usually with 
severe asthma and referred to as the “Samter’s triad” [Samter M et al., 1968]. 
Moreover, several arachidonic acid metabolism abnormalities have been linked to 
AERD patients, mainly in terms of cyclooxygenase (COX) inhibition [Kowalski 
ML et al., 2000] and increased production of leukotrienes [Pérez-Novo CA et al., 
2005; Owens JM et al., 2006; Adamjee J et al., 2006]. 
1.2.1.5  Immunocompromised s tate  
Primary and acquired immunodeficiencies, determining dysfunction of the 
immune system, may manifest with CRS [Fokkens WJ et al., 2012].  
 
Studies investigating other dubious predisposing factors, including pregnancy and 
the endocrine state, local host factors (e.g. anatomic variations), environmental 
factors (e.g. cigarette smoke and lifestyle-related), iatrogenic factors (surgery-
related), Helicobacter pylori and laryngopharyngeal reflux, are often contrasting and 
unable to verify a clear causal correlation with CRS [Fokkens WJ et al., 2012]. 
 
1.2.2 Pathogenetic hypotheses 
 
Historically, idiopatic CRS was attributed to either the end stage of an 
incompletely treated case of acute rhinosinusitis (CRSsNP) or severe atopy 
(CRSwNP). The limitations of these assessments were clear to many but relatively 
few hypotheses have been proposed as alternatives. 
 
The first attempt to address aetiology and pathogenesis in broad terms was the 
“fungal  hypothes is” which attributed all CRS to an excessive host response to 
Alternaria fungi [Ponikau JU et al., 1999] (Figure 1-1). This theory proposes that 
patients with CRS mount an eosinophilic response to fungi. [Braun H et al., 2003; 
Ponikau JU et al., 2007].  
 
Defec ts  in the e i cosanoid pathway , most closely associated with aspirin 
intolerance [Kowalski et al., 2007], have also been proposed as a potential cause of 
CRSwNP in general. Specifically, increased synthesis of pro-inflammatory 
leukotrienes, down-regulation of COX-2 and reduced levels of anti-inflammatory 
prostaglandins (PGE2) have been proposed as a mechanism not just for aspirin-
sensitive nasal polyps but also aspirin-tolerant CRSwNP [Pérez-Novo CA et al., 
2005; Van Crombruggen K et al., 2011; Roca-Ferrer J et al., 2011]. While some 
theoretical evidence supports this line of thought in CRSwNP, enthusiasm is 
muted by the limited clinical efficacy of leukotriene pathway inhibitors [Fokkens 
WJ et al., 2012]. 
 
1.2.3 The role of microorganisms in chronic rhinosinusitis 
 
Bacteria have an established role in the aetiology of acute rhinosinusitis and it has 
long been speculated that incompletely treated bacterial acute rhinosinusitis leads 
to the development of CRS. While bacteria may trigger acute infectious 
exacerbations, the role of bacteria in the initial establishment of CRS remains 
unclear. Studies of the bacteriology of the sinonasal cavities in patients with CRS 
has yielded highly variable results, although many have found evidence for greater 
prevalence of certain bacteria, such as Haemophilus influenzae, Moraxella catarrhalis, 
Pseudomonas aeruginosa, Streptococcus species and Staphylococcus aureus, particularly in 
patients with acute exacerbations of CRS [Benninger MS et al., 2003]. 
 
Different theories were pointed out to explain the role of bacteria in the persistent 
inflammation of the sinuses in CRS, their ability to escape the host innate and 
adaptive defences and their increased resistance to antibiotics: 
- establishment of bacterial biofilms on the mucosal layer 
- intracellular residence of bacteria 
- qualitative and quantitative modifications in the sinusal microbiome 
 
Biof i lms  have been suggested as a potential entity that can cause CRS [Foreman A 
et al., 2011]. It can be speculated that a defect in the immune barrier might 
facilitate formation of biofilms (q.v. section 1.4 for details). The mechanism of 
biofilm formation and worsening of CRS remain unclear but biofilms on the sinus 
mucosa have been linked to those mediating periodontal disease [Ohlrich EJ et al., 
2009]. Once established, biofilm induce significant changes in the mucociliary 
layer, as demonstrated by the marked destruction of the epithelium with complete 
absence of cilia in biofilm-associated CRS [Galli J et al., 2008; You H et al., 2011]. 
The resulting mucociliary impairment is then likely to promote further bacterial 
adherence and prevent bacterial clearance by the host’s immune system. 
Interestingly, when bacterial biofilms are observed in areas of epithelial damage, 
there is a consistent elevation of T-lymphocyte and macrophage numbers, 
indicating a local inflammatory response [Wood AJ et al., 2011]. 
The “s taphylococcal  superant igen (SAg) hypothes is” proposed that exotoxins 
foster nasal polyposis via effect on multiple cell types. Staphylococcus aureus, perhaps 
protected by biofilms or sequestered within epithelial cells, secrete SAg toxins that 
result in a generalized stimulation of T-cells, cytokines release and local polyclonal 
IgE response, all of which stimulate eosinophil recruitment and the clinical and 
histopathological changes associated with CRSwNP [Bachert C et al., 2001; 
Seiberling KA et al., 2005].  
Although the fungal and super antigen hypotheses are often presented as opposing 
or competing viewpoints, they essentially agree on one salient feature: both imply 
that unnamed host factors determine disease susceptibility to common 
environmental elements.  
 
The concept of a dysfunctional host-environment interaction actually forms the 
basis of another line of current research into CRS aetiology and pathogenesis. The 
host sinonasal epithelium serves as the site of interface with inhaled irritants, 
commensal organisms and pathogens. Mucociliary clearance (MCC), physical 
exclusion and the innate and acquired immune responses are used to separate host 
from environment. Broadly speaking, when components of these defenses fail, 
chronic mucosal inflammation ensues and the CRS syndrome is the symptomatic 
result. This line of thought gives rise to the “immune barr ier  hypothes is” of CRS, 
wherein host defects are the key to aetiology and pathogenesis [Kern RC et al., 
2008]. The shifting emphasis away from environmental and microbial agents 
toward identifying host susceptibility is well established in other chronic 
inflammatory diseases involving epithelial surfaces such as atopic dermatitis, 
psoriasis, asthma and inflammatory bowel disease (IBD) [O'Regan GM et al., 
2008; Groschwitz KR et al., 2009; Swindle EJ et al., 2009]. This theory proposes 
that defects in the co-ordinated mechanical barrier and/or the innate immune 
response of the sinonasal epithelium manifests as CRS. These defects theoretically 
lead to increased microbial colonization with a panoply of microbial agents, 
accentuated barrier damage and a compensatory adaptive immune response [Tieu 
DD et al., 2009]. 
 
1.3 Focus on the sinus mucosa 
1.3.1 Mechanical and immunologic barrier 
 
Structurally, the nasal mucosa consists of an epithelial layer of ciliated, 
pseudostratified, columnar cells joined by tight junctions, interspersed with goblet 
cells. Beneath the epithelium reside lymphocytes, plasma cells, macrophages, 
dendritic cells (DC), vascular arcades and glands. Ciliary motility and the structural 
integrity of the epithelium serve as mechanical factors limiting antigenic 
stimulation. 
Under optimal conditions, the upper airways and sinuses readily clear these 
materials and destroy or eliminate them without involvement of the adaptive 
immune system. When this process fails, microorganisms may flourish on the 
mucosa and acute or chronic inflammation can result. If the barrier function of 
the epithelial layer fails, otherwise innocuous materials may gain access to cells of 
the immune response in and below the lamina propria, further stimulating the 
inflammatory process [Schleimer RP et al., 2009]. Regardless the inciting antigen, 
allergens, fungi and bacteria often have proteolytic activity, which may diminish 
epithelial integrity, while viruses often have the capacity to lyse epithelial cells; all 
of these agents expose the underlying tissue to foreign stimulation. Despite these 
exposures, epithelial integrity is usually maintained and, when injury does occur, 
repair processes restore the mechanical barrier. 
Thus, mechanical barriers, effective MCC and optimal healing limit the degree of 
antigenic stimulation of immune cells residing in the mucosa. Despite this 
impressive barrier function, animate and inanimate matter will stimulate the 
mucosal immune system, which must distinguish between commensal organisms 
and potential invading pathogens without excessive tissue damage.  
 
1.3.1.1  Defec ts  in the mechanical  barr ier  
 
A number of genes implicated in chronic inflammatory mucosal disorders other 
than rhinosinusitis (asthma, psoriasis, atopic dermatitis, IBD) have been tested 
also on epithelial cells from CRS patients. These studies uncovered a marked 
decrease in the expression of mRNA for S100A7, S100A8, S100A9 and SPINK5 
[Richer SL et al., 2008]. S100 family proteins are antimicrobial peptide acting as 
nonchemokine chemoattractants of inflammatory cells, regulated by T-cell 
cytokine IL-22, and appear to have a role in epithelial growth dynamics and repair. 
SPINK5 is a secreted antiprotease necessary for barrier function of the skin. It 
protects gap junctions from the attack of proteases derived from host sources or 
microbes and allergens. The effect of the subsequent loss of epithelial integrity is 
an increase in epithelial cell death with exposure of TRL ligands to PAMPs and an 
accentuated inflammatory reaction [Holgate ST, 2007].   
 
1.3.2 Regulation of immune responses of the epithelium  
1.3.2.1  Innate Immune response  
 
The innate immune system refers to inborn resistance that is present before the 
first exposure to a pathogen. Innate responses are initiated by membrane-bound 
and cytoplasmic pattern recognition receptors (PRRs) that recognize pathogen-
associated molecular patterns (PAMPs) [Janeway CA Jr et al., 2002], which are 
conserved molecular patterns common among significant numbers of pathogens. 
Recognition of PAMPs by PRRs serves as a “danger” signal to the host immune 
system [Akira S et al., 2006]. PRRs also identify cellular damage through detection 
of debris from necrotic cells and the combined recognition of danger and damage 
signals sets in motion a response consisting of endogenous antimicrobial, antiviral 
and antiprotease products designed to aid pathogen clearance and preserve the 
epithelial barrier [Meylan E et al., 2006]. In addition to the release of innate 
protective agents, PRRs activation triggers the release of chemokines and 
cytokines mediating the activation of antigen-presenting cells (APCs) and the 
attraction of innate cellular defenses such as neutrophils and ultimately determines 
the nature of the acquired immune response [Iwasaki A et al., 2004].  
The two best-characterized classes of PRRs are the toll-like receptor (TLR) family 
and the NOD-like receptor (NLR) family [Akira S et al., 2006; Meylan E et al., 
2006]. TLRs are transmembrane receptors expressed on multiple cell types 
including respiratory epithelial cells [Lane AP, Truong-Tran QA, Myers et al., 
2006]. On activation of TLRs, epithelial cells may initiate production of defensive 
molecules specific to a particular pathogen (e.g. TLR2 plays a prominent role in 
responses to Gram-positive bacteria [Akira S et al., 2006]) and transmit the danger 
signal to alert the appropriate elements of the adaptive immune system [Matzinger 
P, 2002]. The NLR family includes NOD1 and 2, which are important in the 
recognition of bacterial cell wall products including staphylococci [Fournier B et 
al., 2005]. 
 
1.3.2.1.1 Defects in the innate immune barrier  
 
A diminished IL-6/STAT3 response may lead to minimal Th17 response, 
increased IgE and Staphylococcus aureus colonization [Peters AT et al., 2009], as if 
there was a local equivalent of the hyper-IgE syndrome (Job’s syndrome) [Holland 
SM et al., 2007].   
 
1.3.2.2  Acquired Immune response 
 
The transition to an acquired immune response is the result of a sufficiently strong 
PAMP stimulus. Tissue DCs are particularly important in generation of the 
acquired immune response, acting as APCs. After stimulation by PRRs through 
PAMP recognition, DCs become activated, cease phagocytic activity and acquire 
chemokine receptors that lead them to migrate to lymph nodes where they present 
antigen to Th cells. IL-6 has been proposed to be a key cytokine mediating the 
transition between the innate and acquired immune responses, helping to shut 
down many components of the innate response and promoting the acquired 
response [Jones SA, 2005].  
The subsequent Th responses have classically been divided into Th1 and Th2 
based on cytokine profiles. Th1 responses (IL-12 and IFN-γ) facilitate defense 
against intracellular pathogens. Th2 responses (IL-4, IL-5 and IL-13) are of 
primary importance in parasitic immunity and are associated with allergy and 
asthma. The type, duration and intensity of the PAMP stimulus shape the cytokine 
milieu and are believed to be critical in determining the Th profile. 
 
 
Figure 1 – Pathogenetic mechanisms of CRS (Reprinted with permission 
3997040216197 from [Bachert C et al., 2016]) 
 
A, CRSwNP. In a TH2-type microenvironment with general lack of regulatory T 
(Treg) cell function, the epithelial cell activation by microbes induces thymic stromal 
lymphopoietin (TSLP), IL-25, and IL-33 production. This leads to Th2 and ILC2 
response. IL-5 induces eosinophilia, and IL-4 and IL-13 induce local IgE production. 
An alternatively activated macrophage subset contributes to the inflammation. 
Activated epithelial cells die, with apoptosis resulting in a compromised epithelial 
barrier.  
 
 
B, CRSsNP. Instead of a TH2-skewed T-cell response, a TH1, TH17, or a mixed TH0 
response predominates, neutrophilia is often associated, and expression of TGF-b and 
its receptors is increased. IL-6, IL-8, IL-17, and type 1 interferons play important roles. 
CRS, Chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; 
CRSwNP, chronic rhinosinusitis with nasal polyps; DC, dendritic cell. 
 
 
Additional Th subsets besides Th1 and Th2 have recently been recognized, 
including Th17 and Treg cells [Tato CM et al., 2006]. Th17 responses are thought 
to play a role in defense against extracellular bacteria and Treg cells mediate 
immunosuppression and immune tolerance. Several cytokines, including IL-6, 
TGF-β1 and IL-23, appear to be key factors in fostering a Th17 response. TGF-
β1 also promotes Treg differentiation, except in the presence of high IL-6, in 
which case this response is suppressed. Th1 and Th2 responses reciprocally inhibit 
one another and both suppress Th17 responses [Tato CM et al., 2006]. Treg cells 
appear to suppress Th1, Th2 and Th17 responses, acting to limit excessive 
immune responses [Romagnani S, 2006]. Treg responses are inactivated in situ by 
strong PRR stimulation, most prominently TLR2 [Liu H et al., 2006]. These 
permit active protective responses to be mediated at the sites of a strong PAMP 
stimulation while suppressing excessive or inappropriate immune responses. 
In summary, the mechanical and innate immune barriers across the nasal mucosa 
serve to appropriately repel the constant load of exogenous stimulation and limit 
activation of the acquired immune response. Genetic and/or acquired defects in 
this complex process may at least theoretically lead to the development of chronic 
inflammation seen in CRS [Ramanathan M Jr et al., 2007; Schleimer RP et al., 
2007]. 
 
1.3.2.2.1 Defects in the transition from innate to acquired immune response 
 
An aberrant communication and signaling between the innate and acquired 
responses may represent another potential mechanism for CRS development. As 
previously mentioned IL-6 has been proposed as key cytokine mediating this 
transition. Its main action is to free helper and effector T-cells from the 
suppressive effects of IL-10 secreted by Treg. The described association of 
elevated IL-6 and IL-6 receptor in CRSwNP (possibly mediated by TLR2 or PAR 
stimulation) might be sufficient to inhibit local innate immune responses and 
dampen local adaptive immunosuppression mediated by Treg cells, suggesting that 
derangement of this signaling pathway may be significant for polyp formation 
[Peters AT et al., 2010].  
Lastly, there are studies also suggesting a dysfunction of the BAFF (B-cell 
activating factor of the TNF family) regulatory pathways in CRSwNP, together 
with elevated IgA. BAFF is a secreted epithelial factor instrumental in fostering 
local immunoglobuling responses, in particular B-cell proliferation and class switch 
recombination. The hypothesis is that BAFF, through B-cell proliferation, class 
switch recombination and production of IgA, indirectly influence mediator release 
from eosinophils and subsequent mucosal oedema characteristic of NPs [Kato A 
et al., 2008] (Figure 2). 
 
Figure 2 - Key phenotypes and proposed endotypes of CRS and their possible 
associations (Adapted from [Akdis CA et al., 2016]) 
 
ASA, Aspirin; CRS, chronic rhinosinusitis. 
 
1.3.3 Histomorphological features and tissue remodelling 
 
Remodelling is a critical aspect of wound repair in all organs and it is a dynamic 
process resulting in both ECM production and degradation. This may lead to a 
normal reconstruction process with production of normal tissue or may result in 
pathological reconstruction with formation of pathological tissue [Bousquet J et 
al., 1992]. 
Remodelling in the lower airway disease has been extensively studied. It includes 
changes in airway epithelium, lamina propria and submucosa, resulting in airway 
wall thickening. The main histologic features of remodelling are macrophage and 
lymphocyte infiltration, fibroblast proliferation, angiogenesis, increased connective 
tissue formation (fibrosis) and tissue destruction [Bai TR, 2010].  
There is evidence that remodelling is also present in chronic sinus disease and 
distinct remodelling features differentiate different subgroups of CRS. 
As already mentioned, CRS is divided in CRSsNP and CRSwNP on the basis of 
different inflammatory and “remodelling patterns” [Huvenne W et al., 2009]. 
 
Several factors have been implicated in remodelling. TGF-β is a pleiotropic and 
multifunctional growth factor with immunomodulatory and fibrogenic activity, 
known in 3 different isoforms (TGF-β1, β2 and β3), which can bind to 3 
membrane receptors (TGF-β RI, RII and RIII). It is considered a counter 
regulatory cytokine to resolve inflammation and to initiate the repair process. 
Indeed, it acts as chemoattractant and proliferation factor for fibroblasts, inducing 
synthesis of EMC proteins [Van Bruaene N et al., 2008].  
Furthermore, TGF-β regulates the function of immune cells. It is a strong 
suppressor of T-cell activation and of antibody secretion by B-cells and acts both 
as an effector and an inductor of Treg function.  
TGF-β1 protein expression was found increased together with TGF-β RI 
expression, indicating an enhanced TGF-β signalling in CRSsNP. In contrast, in 
CRSwNP a low TGF-β1 protein concentration and a decreased expression of 
TGF-β RII indicate a low level of TGF-β signalling. These findings were reflected 
by the remodelling patterns observed, characterized by a lack of collagen in 
CRSwNP and excessive collagen production with thickening of the collagen fibres 
in the ECM in CRSsNP [Van Bruaene N et al., 2009].  
Another possible mechanism implicated in pathologic tissue remodelling is the 
imbalance between matrix metalloproteinases (MMPs), a family of zinc-dependant 
and calcium-dependant endopeptidases, and the tissue inhibitors of MMP (TIMPs) 
[Van Bruaene N et al., 2011]. In CRSsNP, elevated levels of MMP-9 and TIMP-1 
together with high levels of TGF-β1 are found. TGF-β1 induces the release of 
TIMP-1, inhibiting the proteolytic activity of MMP-9. In CRSwNP, only MMP-9, 
but not TIMP-1, is up-regulated, due to the relative lack of TGF-β1.  
 
Lastly, even fibrinolytic components may have a role in tissue remodelling in CRS, 
inducing ECM degradation and breakdown. Plasminogen activators (in particular 
urokinase plasminogen activator [uPA]) play an important role in the fibrinolytic 
system, as these proteins convert the proenzyme plasminogen into the active 
enzyme plasmin. Plasmin degrades fibrin and converts inactive promatrix MMPs 
into active MMPs. This activity is counteracted by plasminogen activator inhibitor-
1 (PAI-1), which is activated by TGF-β1. The PAI-1/uPA ratio of CRSwNP was 
significantly lower when compared with CRSsNP or controls, suggesting that the 
activity of uPA may be dominant in CRSwNP compared with the other groups. In 
CRSsNP, TIMP-1 up-regulation together with MMP-9, high level of TGF-β1 and 
low activity of uPA were observed, so that fibrosis is considered to proceed in the 
ECM [Eloy P et al., 2011] (Table 3). In contrast, in CRSwNP, TIMP-1 is not up-
regulated, and high level of MMP-7 and MMP-9, high activity of u-PA, and low 
level of TGF-β1 are observed, so that fibrinolysis is considered to proceed in the 
ECM [Sejima T et al., 2011]. 
 
 
 
 
 
Table 3 - Inflammatory pathways, cytokine profiles, biomarkers, and tissue remodeling 
in CRS (Reprinted with permission 3997110379476 from [Eloy P et al., 2011]) 
 
AA arachidonic acid, AERD aspirin-exacerbated respiratory disease, COX 
cyclooxygenase, CRS chronic rhinosinusitis, ECP eosinophil cationic protein, FoxP3 
forkhead box P3, GATA-3 GATA-binding protein 3, GM-CSF granulocyte-
macrophage colony-stimulating factor, ICAM intercellular adhesion molecule, IFN 
interferon, IL interleukin, MMP matrix metalloproteinase, MPO myeloperoxidase, 
RANTES regulated on activation, normal T-cell expressed and secreted, Tbet T-box 
transcription factor, TGF transforming growth factor, Th T-helper type cell, TIMP 
tissue inhibitor of metalloproteinases, TNF tumor necrosis factor, URTI upper 
respiratory tract infection, VCAM vascular cell adhesion molecule, VEGF vascular 
endothelial cell growth factor. 
 
1.4 Genetics of chronic rhinosinusitis: state of the art 
 
Classic evidence for a genetic component of a disease is the heritability of the 
condition. Although formal heritability studies are not available for CRS, a genetic 
basis has long been suspected [Bossé Y et al., 2009]. One early report documented 
cases of concordant monozygotic twins who had CRSwNP despite distinct 
environmental exposure [Drake-Lee A, 1992]. Similarly, familial aggregation of a 
disease points to a genetic basis, and indeed, reports of families with an unusually 
high prevalence of CRS are available [Cohen NA et al., 2006; Delagrand A et al., 
2008]. Additionally, patients with CRS are more likely to report a positive family 
history than those without CRS [Greisner WA 3rd et al., 1996]. Supportive 
evidence for a genetic basis also includes the fact that several syndromes 
associated with known genetic defects have CRS as a clinical component. This 
includes primary ciliary dyskienesia [Noone PG et al., 2004], as well as monogenic 
diseases, such as cystic fibrosis [Armengot M et al., 1997; Sobol SE et al., 2002]. 
Lastly, the inflammatory features of CRS have similarities to those seen in patients 
with allergic rhinitis and asthma, two complex diseases with well-established 
genetic components [Dávila I et al., 2009; Ober C et al., 2011] and strong clinical 
associations with CRS [Fokkens WJ et al., 2012]. Indeed, studies have 
demonstrated common molecular and cellular aspects of these disorders, leading 
to the unified airway concept, which postulates that the common clinical 
manifestations of CRS, allergic rhinitis and asthma suggest a shared cause [Krouse 
JH et al., 2007]. 
 
1.4.1 Limitations of existing literature on genetics of chronic 
rhinosinusitis  
 
No large genetic studies of CRS have been performed to date.  
The aetiology of CRS is likely multifactorial and genes relevant to CRS are likely to 
have small effect sizes, similar to other complex multifactorial diseases [Cho JH et 
al., 2011] 
The majority of studies, available in the international literature, testing whether 
genetic variation is associated with CRS, have used a candidate gene approach . 
This compares the allele frequencies of SNPs in genes suspected a priori to be 
involved in CRS among patients with CRS and those without CRS (control 
subjects). However, there are several limitations to this strategy: (1) the difficulty 
to generate novel information on disease mechanisms because candidates are 
selected based on what is already known (or suspected) about disease biology, (2) 
the difficulty of achieving adequate power, (3) the potential for confounding by 
ancestry when subject groups are heterogeneous and (4) the caveat that an 
association between CRS and a polymorphism does not necessarily indicate 
causality. Subjects groups have to be very carefully selected. 
Genome-wide approaches  overcome the first limitation because of their ability to 
interrogate the entire genome in an unbiased, hypothesis-independent fashion. 
However, to date, such studies are rare in patients with CRS. There are several 
reasons for the paucity of genome-wide association studies (GWASs), including 
the need for a large number of well-phenotyped subjects, the expense of high-
density genotyping and the lack of research consortia in this field. By the way, 
GWASs have proved to be fruitful for identifying novel pathways and providing 
new insights into disease biology. 
 
1.4.2 Current evidences from candidate gene approaches  
 
A recent extensive review extracted the most promising findings from candidate 
gene studies present in the current literature regarding the genetics of CRS [Hsu J 
et al., 2013]. 
Epidemiologic and genetic reports support a relationship between CFTR and CRS 
independent of cystic fibrosis. The high prevalence of CRS among patients with 
CF [Ramsey B et al., 1992] suggests that CFTR might contribute to the 
pathogenesis of CRS and this relationship might extend beyond patients with 
clinical features of CF. Indeed, a landmark case-control study demonstrated that 
patients with CRS were more likely to be CFTR carriers compared with control 
subjects (7% vs 2%), although CFTR mutations were present in only a minority of 
the whole group of CRS patients (5%) [Wang X et al., 2000]. 
A relationship between CRS and HLA genes variation (both class I and class II) is 
intriguing but still unclear. HLA plays a critical role in antigen presentation and 
represents an important link between innate and adaptive immunity [Chaplin DD, 
2010]. HLA genes variation has been strongly associated with several 
inflammatory diseases, such as insulin-dependant diabetes mellitus and ankylosing 
spondylitis [Cho JH et al., 2011]. Several groups have examined variation in HLA 
in patients with CRS (mainly CRSwNP) and identified alleles associated with the 
disease, the most robust of which is represented by the association between CRS 
and HLA-DRB1*04 allele (OR, 2.2; 95% CI 1.2-4.2; p = 0.009) [Ramírez-
Anguiano J et al., 2006], but only few attempts have been made to replicate them. 
Nevertheless HLA loci remain attractive candidate genes because of the significant 
immune dysregulation that is characteristic of CRS [Lane AP, Truong-Tran QA, 
Schleimer RP, 2006]. 
A growing body of evidence suggests that aberrant immunity and aberrant 
remodelling of sinonasal epithelial tissue might underlie the pathogenesis of CRS 
[Tan BK et al., 2010].  
A few studies have investigated whether genetic variation in the arachidonic acid 
pathway is associated with CRS, with controversial results [Pérez-Novo CA et al., 
2005; Gosepath J et al., 2005].  
 
1.4.3 Insight from genome-wide approaches: pooling-based GWAS  
 
Two pGWASs of patients with CRS have been published. Unlike traditional 
GWASs, this approach relies on pooled DNA from multiple subjects for analysis, 
which reduces the genotyping costs.  
The first study identified novel associations between CRS and variation in genes 
involved in the basement membrane formation: laminin α2 (LAMA2), laminin β1 
(LAMB1) and the acyloxyacyl gene (AOAH) [Bossé Y et al., 2009]. The AOAH 
gene is particularly interesting because it contributes to host defence against 
bacterial lipopolysaccharide and has also been linked to asthma. Moreover, the 
association between AOAH (rs4504543) and CRSsNP has been replicated in a 
candidate gene study of Chinese patients (OR, 0.30; p = 8.11x10-11) with a 
statistical significance even after multiple statistical testing [Zhang Y et al., 2012].  
The second pGWAS found an association between CRS and variation in the 
epithelial tumor protein p73 gene (TP73) [Tournas A et al., 2010], which is 
supported by separate studies that reported abnormal expression of the p73 
protein in the sinonasal tissue of patients with CRSwNP [Li CW et al., 2011]. 
 
1.4.4 Gene-environment interactions: is there a role for epigenetics?  
 
The variation of clinical phenotype indicates that even in CF, the most straight-
forward case of genetic CRS, multiple factors in an individual patient strongly 
determine disease expression [Hull J et al., 1998].  Alterations in expression of 
genes other than CFTR, mediated via genetic variation or environmental effects, 
apparently combine to affect disease phenotype. 
The effects of changing environment on prevalence of CRS have not been directly 
studied but it is certainly reasonable to hypothesize that many of the same 
environmental factors that influence the prevalence of atopy also influence the 
prevalence of CRS [Liu AH et al., 2003].  
In brief, CRS phenotype most likely results from the combined effect of genetic 
variation and acquired epigenetic effects across critical pathways that control the 
immunobiology of the nasal mucosa. Epigenetic changes create de facto genetic 
changes by altering gene expression without directly altering the DNA sequence. 
1.5 Gene-expression studies  
 
The gene-expression is the process through which the information codified in a 
gene are used to synthetize a functional gene product, usually a protein. This 
process is applied by all known life, from viruses to multicellular eukaryotes.  
Measuring gene-expression is an useful tool in many life sciences since the ability 
to quantify the level at which a particular gene is expressed in a cell, a tissue or a 
an organism can provide lot of  helpful information, for instance determining an 
individual’s susceptibility to a cancer by the identification of an oncogene 
expression. 
Gene-expression studies are based on the identification of a “target” gene thought 
to be involved in the pathological mechanism of a disease through the analysis of 
the transcriptome, i.e. the set of all messenger RNA molecules in one cell or a 
population of cells. Even if it is known that the expression of a lot of genes is 
performed by pre-transcriptional mechanisms and, by consequence, high 
concentration of mRNA are not always correlated with high concentration of the 
corresponding protein, it remains a mainstay of the gene-expression measurement. 
The levels of mRNA can be quantitatively measured by northern blotting: a 
sample of RNA, separated on an agarose gel, is hybridized to a RNA probe 
marked with a radioactive reagent and than detected by an autoradiograph. The 
main disadvantages of this technique are related to the relatively large quantities of 
RNA needed and the not complete accuracy in the quantification of the RNA, 
since it is based on the measuring of the band strength in an image of a gel. On 
the other hand the main advantage of this technique lays on the possibility to 
discriminate alternately spliced transcripts.  
Another approach for the quantification of mRNA is the reverse transcription 
followed by the quantitative PCR (RT - qPCR). The RT PCR generates a DNA 
template from the mRNA. The single-stranded template is called cDNA and is 
then amplified in the quantitative step. During this second procedure the 
fluorescence emitted by a labelled hybridization probe of the target gene change as 
the DNA amplification process progress. With a standard curve “ad hoc” made 
qPCR produce an absolute measurement of the number of copies of the original 
mRNA (usually in units of copies per nanolitre of homogenized tissue). Generally 
the expression of the target gene is normalized to the expression of an 
housekeeping gene that should be equal represented in the sample analysed.  
This technique is very sensitive (even the detection of a single mRNA copy is 
theoretically possible) and may be utilized for numerous genes simultaneously 
(expecially in low-density array), but can be expensive in relation to the kind of 
used probe. 
As alternative The Real-Time PCR can be performed using the iTaq™ Universal 
SYBR® Green Supermix (BioRad, Italy), which we used in our study. 
The SYBR Green is an aromatic organic compound (molecular formula 
C32H37N4S) part of the asymmetric cyanine group, molecules with fluorofor 
activity and is used in Molecular Biology as colorant of Nucleic Acid. 
The SYBR Green is an intercalating agent (molecule, usually planar,  capable to fit 
transversely in the DNA filaments, through a mechanism discovered by Leonard 
Lerman and called intercalation) and binds preferentially a double-stranded DNA 
(dsDNA). Complex DNA-colorant absorbs blue light at a wavelength λmax = 488 
nm and emits green light λmax = 522 nm. 
Thanks to their hydrophobic properties, intercalating agents are able to fit between 
two adjacent nitrogen bases along the strands of the double helix. When the cell 
begins his replicative cycle and the point where the intercalating agent inserted is 
reached from DNA polymerase, this does not distinguish it from the adjacent 
nitrogen bases and proceeds by inserting a nucleotide which makes pair with the 
intercalating agent. 
The reading of the fluorescence is made at the end of each amplification cycle of 
the PCR. The use of intercalating fluorescent molecules is an effective and 
relatively economic method, however this system is not able to discriminate 
between the specific amplification products and other nonspecific products such 
as primer dimers. It’s therefore essential to draw the primer with low-risk of 
dimerization. 
Other methods used to quantify simultaneously many different mRNA is the 
hybridization microarray, in which a single array or “chip” may contain probes to 
identify transcript levels for all the genome of the organism. 
Studies on gene expression related to nasal polyposis are present in literature but 
still limited. 
 
1.6 Replication studies  
 
A replication study involves repeating an original study using the same methods 
but with different subjects and experimenters. The researchers will apply the 
existing theory to new situations in order to determine generalizability to different 
subjects, age groups, races, locations, cultures or any such variables. 
 
The main determinants of  a replication study include: 
▪ To assure that results are reliable and valid 
▪ To determine the role of extraneous variables 
▪ To apply the previous results to new situations 
▪ To inspire new research combining previous findings from related studies 
 
When we perform the deliberate repetition of previous research procedures in our 
clinical setting we can be able to strengthen the evidence of previous research 
finding, and correct limitations, and thus overall results may be in favor of the 
results of previous study or we may find completely different results. 
 
A replication study of an original study is possible and should be carried out, 
when: 
▪ The original research question is important and can contribute to the body of 
information supporting the discipline 
▪ The existing literature and policies relating to the topic are supporting the topic 
for its relevance 
▪ The replication study if carried out carries the potential to empirically support 
the results of the original study, either by clarifying issues raised by the original 
study or extending its generalizability. 
▪ The team of researchers has all expertise in the subject area and also has the 
access to adequate information related to original study to be able to design and 
execute a replication. 
▪ Any extension or modifications of the original study can be based on current 
knowledge in the same field. 
▪ Lastly, the replication of the same rigor as was in original study is possible 
[Explorable, 2009].  
 
 
 
 
 
 
 
 
2 MATERIALS AND METHODS  
 
Our study was carried out in the DBSV biology laboratories of the Insubria 
University Varese, in collaboration with the Otorhinolaryngoiatric Clinic of the 
Ospedale di Circolo and Fondazione Macchi, and the aim was to verify the 
expression of certain genes in patients suffering from chronic rhinosinusitis.   
We decided to replicate some of the most significant studies leaded on this field, 
concerning gene expression evaluation in patients affected by inflammatory 
diseases of paranasal sinuses,  trusting in the importance of replication studies. 
 
2.1 Selected genes 
 
We decided what genes have to be investigated analysing the studies published in 
the international literature over the past 10 years concerning gene expression in 
CRS and, given the significant results, we chose the following nine genes as 
possible target genes involved in the physio-pathogenesis of chronic rhinosinusitis:      
 
1) COX 2  
2) Acquaporin  
3) Caveolin  
4) Mammaglobin  
5) MUC5AC  
6) PGDS  
7) TNF alpha  
8) TGF beta  
9) Lactoferrin  
 
 
1- COX 2 
It is believed that one of the possible pathogenic mechanisms involved in nasal 
polyposis is due to an impairment in prostanoid metabolism. Prostanoids are 
produced from arachidonic acid when this is released from the plasma membrane 
by means of phospholipases and is metabolised by cycloxygenation (COX) and 
specific isomerases.  Prostanoid production therefore depends upon the activation 
of the two COX isoenzymes associated with the cells. While COX 1 is expressed 
in a constitutive manner in many cells, the COX 2 isoenzyme is only minimally 
expressed, though it can be induced as a response to various forms of stimulation  
[Mullol J et al., 2002], such as cytokines or growth factors.  COX 2 resulted to be 
over-expressed in inflammatory diseases [Pujols L et al., 2004]. 
 
2- Acquaporin: 
Acquaporins are a family of small hydrophobic membrane proteins that appear to 
play a role in the homeostasis of mucosal barrier function by regulating tissue 
water transport. In chronic rhinosinusitis, and particularly when this is associated 
with nasal polyposis, there is probably a fault in the nasal epithelial barrier and 
reports of a decrease in AQP5 in subjects suffering from CRS demonstrate that 
this has a fundamental role in the relative homeostasis [Frauenfelder C et al., 2014; 
Shikani AH et al., 2013]. 
 
3- Caveolin 
Caveolin-1 is a 22kDa scaffolding protein with a central role in defence against 
infections and in tumour suppression by reducing the production of Cyclin D1 
and endothelial nitric oxide synthase. Its role in the pathogenesis of rhinosinusitis 
inflammation was considered after a reduction in the gene expression in this 
protein was discovered in patients affected with CRS, especially in the form 
associated with polyposis [Lin H et al., 2014]. 
4- Mammaglobin 
Mammaglobulin A is a 10kDa glycoprotein that probably belongs to the family of 
proteins in which rat estramustin binding protein and human uteroglobin are to be 
found. As yet, the role of mammaglobin is unknown, though the other proteins in 
this family are secretory ones that can both bind steroids and modulate 
inflammatory processes [Forsgren B et al., 1979; Miele L et al., 1994]. 
The mRNA of this protein has been investigated in the oncological field, 
principally in primary breast tumours since it is over-expressed in 50% of the cell 
lines in breast cancer in humans and in 23% of primary breast tumours [Fleming T 
et al., 2000]. 
The role of mammaglobin in nasal polyposis was postulated in the literature after 
the discovery that its expression in the mucosa of healthy subjects differed from 
that in patients with chronic polypoid rhinosinusitis [Chusakul S et al., 2008]. 
 
5- MUC5AC 
MUC5AC is one of the most profusely produced mucins in the respiratory tract, 
and in the sinus areas in particular. Its production is controlled by numerous 
mediators such as interleukin 1beta, 6, 13, 17, and by TNF-alpha [Ding GQ et al., 
2007; Kim YJ et al., 2014]. 
Over-production of this mucin has been considered related to the hypoxic 
conditions believed to be a predominant pathophysiological factor in chronic 
rhinosinusitis. Over-production of mucous results to be one of the prevalent 
characteristics of inflammatory rhinosinusitis.  
 
6- PGDS – prostaglandin D synthase  
Prostaglandin D is a derivative of arachidonic acid and is one of the major cyclo-
oxygenase products. It is generated by PGDS. Together with prostaglandin E, it is 
responsible for mediating airway inflammation through multiple biological 
activities that range from vasodilatation to bronchoconstriction [Okano M et al., 
2006]. 
Certain authors have suggested that PGDS might contribute to the development 
of hyper-eosinophilia, which is known to be one of the factors considered the 
greatest risk for an outcome of chronic rhinosinusitis that is difficult to treat.   
 
7- Tumour necrosis factor alpha (TNF-alpha) 
TNFa is a cytokine implicated in systemic inflammation and plays a central role in 
reaction during the acute stage of the inflammation.  It is produced primarily by 
macrophages, though it can also be produced by many other cell types such as 
CD4+ and NK lymphocytes, neutrophils, mast cells and eosinophils [Swardfager 
W et al., 2010; Park SJ et al., 2013]. Along with other cytokines, mainly IL-6, IL-
12A and IL-13, it is over-expressed in patients with chronic rhinosinusitis.  
 
8- TGFb 
Transforming Growth Factor Beta-1 is a dimer that is intracellularly synthesised 
and extracellularly stored in latent form. Two proteins bind to TGFb1 and control 
its activation: LAP (latency associated peptide) and TGFb binding protein. TGFb1 
belongs to the cytokine family and exists in 3 isoforms (1, 2 and 3). Generally, 
when TGFb is referred to, isoform 1 is intended, since this was the first to be 
discovered in this family.  
The role of TGFb 1 is to control proliferation, differentiation and other functions 
in the majority of cells.   
Some studies have demonstrated how down-regulation of TGFb expression 
activation might be associated with chronic inflammatory diseases in the 
respiratory tract, RSC being one of these [Go K et al., 2010]. 
 
 
9- Lactoferrin  
Lactoferrin is an approximately 80kDa protein binding to iron, first discovered in 
breast secretion, and is synthesised by the majority of the tissues in mammals.  
[Zhang Y et al., 2014]. 
Lactoferrin has various biological properties (anti-cancerogenic, anti-bacteric, anti-
viral, anti-fungal, anti-inflammatory and immunomodulation). One of its 
characteristics that has been the focus of discussion in the literature for several 
years is that it appears to inhibit the growth of fibroblasts in polypoid mucosa 
[Psaltis AJ et al., 2007; Psaltis AJ et al., 2008; Acıoğlu E et al., 2012].  
 
2.2 Patients selection 
 
We decided to compare the gene expression in healthy subjects (not affected by 
CRS; Control Group; C Group) with that of patients with CRS with nasal 
polyposis not associated with plasmatic eosinophilia and other immunologic 
diseases (CRSwNP; Polyps Group; P Group). 
Hyper-eosinophilia is a well-known risk factor for the type of CRS that is poorly 
responsive to treatment and is often one of the implications leading to more 
serious forms of the disease.  
All the patients both from Group C and P, underwent accurate history collection, 
allergologic and pneumologic evaluation and blood tests. 
Patients referring or presenting allergies, ASA intolerance, asthma, immunologic 
diseases, plasmatic hypereosinophilia or presence of infection were excluded from 
the study. 
Diagnosis (Group P) or exclusion (Group C) of CRSwNP was also obviously 
supported by endoscopic examination of the nasal fossae and CT scan without 
mean of contrast of the head. 
If we consider a phenotypical / immunological Classification like the one 
proposed by Stammberger H [Stammberger H, 1999], this study has not taken into 
account classes I and II (responsive to surgery alone and apparently not linked to 
an immunological substrate), and class IV / V of nasal polyposis (that are, the 
types of nasal polyposis that are associated with Hypereosinophilia and systemic 
diseases, such as Kartagener’s syndrome or Cystic Fibrosis); the only class we 
considered was class III. 
 
2.3 Specimens collection 
 
In our study on gene expression we obtained biopsy specimens of 
hyperplastic/polypoid mucosa (Group P) and of healthy mucosa (Group C) taken 
from the anterior ethmoid of the subjects enrolled in the study and submitted to 
general anesthesia for FESS or local anesthesia for polypectomy (Group P) or 
submitted to general anesthesia for septoturbinoplasty (Group C). 
When the biopsies were performed, the patients had to be free from acute 
inflammatory and infectious conditions.  
The patients were also invited to suspend all local corticosteroid treatment (the 
standard maintenance treatment given to NP and ECRSWNP patients) at least 20 
days prior to the biopsy.  
Adequate informed consent was obtained (Figure 3). 
 
 
 
 
 
 
Figure 3 – Informed consent given to patient before biopsies procedures (Italian and 
English versions) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The biopsies took place in operating rooms of the Day Hospital, Day Surgery and 
Ordinary Otorhinolaryngoiatric Clinic of the Circolo and Fondazione Macchi 
Hospital.  
The biopsies for the study required at least 100 mg of tissue. 
At the end of the study, RNA has been isolated from the samples of 85 patients.  
Only the RNA of  24 (28.2%) patient was considered adequate (13 on 35 Group 
C, 37,1%; 11 on 50 Group P, 22%) 
 
DEMOGRAPHY 
10 Female - 14 Male 
Median Age 49,2 
13 patients C group - 11 patients  P Group 
Median Age C group 48,77 - Median Age P Group 49,31 
 
In the interval before starting the investigation, the extracted material was 
preserved either under dry ice and/or in a freezer at -80°C.  
All the material was handled with sterile instrumentation.   
The specimens were processed in the DBSV biology laboratories of the Insubria 
University Varese.   
 
The laboratory process we used, leading to analyse the mRNA expression in the 
biopsy tissue, is the common procedure reported also in literature in all 
comparable studies and is illustrated below. The author was involved in all the 
following steps of the process, supported by experienced Biologist. 
 
 
 
2.4 RNA extraction 
 
The total RNA was isolated starting from approximately 100 mg of tissue, as 
already specified. Each sample was homogenised in 100 ml of H20+DEPC 
(diethylpyrocarbonate for eliminating the RNases), using an UltraTurrax 
homogeniser.  Then 1 ml of TRIzol reagent (SIGMA Invitrogen, Italy) was added 
to approximately 100 mg of the homogenised material obtained. After 5 minutes 
incubation at room temperature, 0.3 ml of chloroform were added for every ml of 
the initial TRIzol; the samples were agitated by hand for 15 seconds, incubated for 
3 minutes and then centrifuged at 12000 x g for 15 minutes at +4°C.  This 
produced two phases: an upper aqueous phase containing the total RNA and a 
lower organic phase containing DNA, proteins and fragments of membrane.    
The upper aqueous phase was retrieved from every sample and the RNA was 
precipitated by adding 0.5 ml of cold isopropanol for every ml of initial TRIzol 
and agitated manually for a few seconds.  
The samples were left under ice for 10 minutes then they were centrifuged at 
12000 x g at +4°C for 10 minutes, thus obtaining pellets of RNA. After 
eliminating the supernatants, the pellets were rinsed with 1 ml of 75% ethanol in 
H20+DEPC for every ml of TRIzol and centrifuged at 7500 x g for 5 minutes at 
+4°C. Each pellet was then air-dried and re-suspended in RNase-free water 
(treated with 0.1% DEPC).   
 
2.5 RNA quantification 
 
The extracted RNA was quantified by QuantiFluor fluorometer (Promega, Italy) 
using QuantiFluor® RNA System dye, according to the instructions of the 
manufacturer. Briefly, at 1 µl of RNA, diluted with 99 µl of TE buffer 1x, were 
added 100 µl of working solution (QuantiFluor® RNA Dye diluted 1:200 with TE 
buffer 1x). The prepared samples were incubated at room temperature for 5 
minutes, protected from light, and then the fluorescence was detected. 
The quality and integrity of the extracted RNA was assessed by gel electrophoresis 
(RNA migration on 1% agarose gel in TAE buffer 1x containing ethidium 
bromide 250 ng/ml, intercalant of the nucleic acids, which permits visualisation 
with a UV transilluminator).  
For each sample, 1 µl of RNA was used, adding 2 µl of 6X Loading Buffer and 
H2O+DEPC to reach a final volume of 12 µl.  
Then RNA was stored at -80 °C until reverse transcription. 
 
2.6 Reverse Transcription  
 
Reverse transcription was performed using the iScript™ cDNA Synthesis Kit 
(BioRad, Italy), starting from 1 µg of RNA,  added with H2O+DEPC  to a final 
volume of 15 µl. After adding 4 µl of iScript  reaction mix and 1 µl of iScript 
Reverse Transcriptase the samples were incubated at 25°C for 5 minutes, 42°C for 
30 minutes, 50°C for 15 minutes and, lastly, at 85°C for 5 minutes in order to 
inactivate the reaction.  The samples were then placed under ice and briefly 
centrifuged. In this manner, the complementary DNA (cDNA) was obtained for 
each sample and was then preserved at -20°C.  
 
2.7 Qualitative PCR  
 
The cDNA of a control sample was amplified by qualitative PCR using the 
primers designed for Real Time PCR, to assess its performance.   
The reagent mix without template was used as the negative control. 
A reagent mix composed as follows:  
- 5 µl of Buffer Green 5X (Promega)  
- 0.5 µl of 10mM dNTPs  
- 0.5 µl of forward primer 50 µM  
- 0.5 µl of reverse primer 50 µM 
- 0.15 µl of Go Tag (Promega)  
- milliQ H2O to reach a final volume of 25 µl 
was added to 1 µl of each cDNA. 
Amplification of the templates was carried out in a thermal cycler (Therma 
Cycler, Applied Biosystems) set as follows:  
- 94°C for 3 mins: first  denaturation of the DNA.  
The successive 25 cycles:  
- 94°C for 30 secs: second denaturation.  
- 60°C for 30 secs: annealing temperature, the primers bind to the complementary 
areas on the DNA.  
- 72°C for 30 secs: lengthening of the filaments. 
Lastly, 72°C for 4 mins to complete the lengthening process.  
 
2.8 Quantitative PCR – Real Time PCR 
 
The Real-Time PCR was performed using the iTaq™ Universal SYBR® Green 
Supermix (BioRad, Italy). Specific primers were designed by Beacon Designer 
Program (BioRad, Italy) within the sequences of the genes showed in Table 4. 
 
 
 
 
 
Table 4 – Sequences used for the selected genes 
 
 
Each reaction tube was set up as follows: 7.5 µl of Sybr Green Supermix (2x), 1 µl 
of forward and reverse primer (6 µM), 1 µl of cDNA (diluted 1:5) and water to a 
final volume of 15 µl were mixed and run in the CFX 96 Thermocycler (BioRad, 
Italy). Thermal cycle was set as here reported: 5 minutes at 95 °C; 10 seconds at 95 
°C and 30 seconds at 60 °C for 40 cycles (Figure 4).  
 
 
 
Gene	Name	 Sequence	5’-3’	
Melting	
Temp	
(°C)	
bp	 Sequence	
Accession	
Number	
TGFβ1																				FW	Primer	
																																Rev	Primer	
CTCGCCAGAGTGGTTATC	 65.9	 120	
NM_000660.5	
GTGTTATCCCTGCTGTCA	 65.4	
Lactoferrin												FW	Primer	
																																Rev	Primer	
CTAATCTCTGTGCTCTGTGTATTG	 63.0	 88	
M93150.1	
CCAGTGTAGCCGTAGTATCTC	 63.2	
TNFα 																							FWPrimer	
																																Rev	Primer	
ATGGCGTGGAGCTGAGAG	 65.3	 78	
HQ201306.2	
TGAAGAGGACCTGGGAGTAGAT	 65.8	
Mammaglobin	A		FW	Primer	
																																Rev	Primer	
GAAGTTGCTGATGGTCCTC	 62.0	 106	 NM_002411.3	
U33147.1	TTGTGGATTGATTGTCTTGGA	 61.7	
AQP5																						FW	Primer	
																																Rev	Primer	
GCTCAACAACAACACAACG	 62.1	 90	
NM_001651.3	
TCAGTGGAGGCGAAGATG	 62.9	
Cox-2																						FW	Primer	
																																Rev	Primer	
GTCTGGTGCCTGGTCTGA	 65.3	 115	
M90100.1	
GTCTGGAACAACTGCTCATCA	 64.5	
MUC5AC																FW	Primer	
																																Rev	Primer	
CATAACTTGTGGTCCTGGAACTA	 63.9	 107	
L46721.1	
CCGAGATTGTGCTGGTTGTA	 64.2	
Caveolin	1														FW	Primer	
																																Rev	Primer	
TGAGCGAGAAGCAAGTGTAC	 64.2	 80	
BT007143.1	
GTCATCGTTGAGGTGTTTAGGG	 65.1	
PGDS																							FW	Primer	
																																Rev	Primer	
TGTAACTTGGGCAGACTTCTACT	 65.3	 123	
NM_014485.2	
GCAGGAATGGCTTGGACTT	 64.6	
Figure 4 - Thermal Cycles 1) Denaturation step (2-3-4) PCR (40 cycles) 5) Thermal 
Protocol for Melting Curves 
 
 
In a first stage we tested the primers of the following three genes to be used in the 
role of housekeeping (Table 5): 
 
GAPDH (Human glyceraldehyde-3-phosphate dehydrogenase):  
GAPDH is an enzyme of approximately 37 kDa and is principally involved in the 
catalysis process in the 6th passage of anaerobic glycolysis [Tarze A et al., 2007]. It 
is an enzyme that is to be found in various tissues and is therefore a good 
candidate for the role of housekeeping gene.  
 
Act_b (Homo sapiens actin beta): actin is a 43kDa globular protein and 
constitutes an abundant proportion (5-10%) of all eukaryote cells.   
beta2-microglobulin (Homo sapiens beta-2 microglobulin): 
beta2microglobulin is a component of the major histocompatibility complex of 
class 1 (MHC class 1) which is present in all the nucleated cells (except in the 
erythrocytes) [Güssow D et al., 1987].  
 
Table 5 – Sequences used for housekeeping selected genes 
 
Melting Curves, which give an indication about the purity of reaction’s product 
(Figure 5, 6, 7) and reveal the possible presence of primer dimers, gave the 
following results for the three housekeeping genes. 
 
 
 
 
 
 
 
 
 
 
Gene Name Sequence 5’-3’ 
Melting 
Temperature 
(°C) 
bp Sequence  
Accession 
Number 
GAPDH                   FW Primer 
                                Rev Primer 
ATCATCAGCAATGCCTCCT 60.9 87 
M17851.1 
GAGTCCTTCCACGATACCAA 60.5 
Act_b                    FW Primer 
                                Rev Primer 
ATGGGTCAGAAGGATTCC 59.8 78 
NM_001101.3 
CTCGATGGGGTACTTCAG 60.3 
Beta2-MG             FW Primer 
                                Rev Primer 
CTATCCAGCGTACTCCAA  88 
AF072097.1 
GAAACCCAGACACATAGC  
Figure 5 - Melting curve for GAPDH. 
 
Figure 6 - Melting curve for BETA-2 microglobulin. 
 
Figure 7 - Melting curve for BETA ACTIN.   
 
 
 
After evaluating the expression of the three candidate genes, GAPDH was chosen 
as housekeeping gene, because of his variability, between the C and the P group, 
lower than the other two analyzed genes (Figure 8). 
 
Figure 8 - Evaluation of the difference of expression of GAPDH between C Group and P Group , in 
choosing the housekeeping gene 
 
2.9 Statistical analysis 
 
The Ct values were recorded and the relative gene expression, expressed as 2–ΔΔCt 
(ΔCt = CtTarget – CtGAPDH and ΔΔCt = ΔCtPolyp samples – ΔCtControl 
samples), was taken as dependent variables. Data analysis was performed by t di 
Student analysis (p < 0.05) in order to determine which mRNAs, measured in polyp 
tissues, were significantly different compared to those evaluated in the control 
tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 RESULTS  
Despite we processed 85 samples, only 24 (28.2%) resulted to have a good quality 
RNA, in which intact 18S and 28S bands were observed. 
 
3.1 RNA extraction – quality  
 
As can be seen in agarose gel electrophoresis of the two Groups (Figures 9, 10), in 
certain samples the RNA results to be partlialy degraded. This occurred 
particularly in the polypoid tissue specimens (Figure 9), showing that the problem 
was probably due to the extraction of non-sufficiently moist tissue or tissue with 
poor cell content.  
 
 
Figure 9 -1% Agarose gel electrophoresis of C GROUP  RNA 
 
 
This problem was clearly less evident in the biopsies taken from healthy mucosa 
from Group C (Figure 10) (37,1% vs 22% of adequate biopsies). 
 
Figure 10 - 1% Agarose gel electrophoresis of P GROUP  RNA 
 
This problem does not seem to have been recurrently reported before in the 
literature and could well be the topic of further investigation as only rarely cited 
[i.e. Nicolis E et al., 1999]. 
 
3.2 Qualitative PCR  
 
The primers designed for Real Time PCR (Beacon Designer 7.91) were tested by 
qualitative PCR to assess functioning (Figure 11).  
 
Figure 11 – 1% Agarose gel electrophoresis: amplification test with primers designed for Real Time 
PCR. 
 
3.3 Quantitative PCR – Real Time PCR 
 
Detected GAPDH as housekeeping gene, we proceeded to evaluate the expression 
of the target genes in Group 1 compared to control Group (Figure 12).  
 
Figure 12 - Evaluation of the difference of expression of the selected genes between C Group and  P 
Group  
 
As reported in figure 12, in P Group samples five out of nine analyzed genes 
showed a statistically significant (p <0.05) change in expression compared to 
controls.  
They all showed a decrease in their expression in NP-CRS group, whether they are 
involved in innate host defense, or in various metabolic pathways, ionic balance or 
transport systems; in particular, lactoferrin and mammaglobin expression 
decreased in a very highly significant way respect to the control. 
The other genes tested showed no significant variations between the two groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 DISCUSSION 
The pathogenetic hypotheses, mentioned in the introduction chapter, for chronic 
rhinosinusitis are less in conflict than might appear. The interplay between 
exogenous agents and host defects conceptually links the theories together, 
although their single validity remains in flux, and under study. 
Host factors that determine susceptibility to CRS depend, in part, on genetic 
variation across key pathways governing the immunobiology of the nasal mucosa. 
Even in case of cystic fibrosis, the prototype of genetic-CRS, a wide variation of 
sinus disease expression is nevertheless observed and multiple genes are involved 
in an individual patient determining clinical phenotype.  
Attempts to identify additional genetic causes have been undertaken, drawn on 
multiple studies on other chronic inflammatory disorders, and this is a work in 
progress. These studies suggest not only the involvement of multiple genetic loci 
but also the importance of environmentally determined epigenetic changes.  
CRS is definitely an heterogeneous disease that can be clinically phenotyped 
according to diverse variables: duration, presence of nasal polyps, recurrence of 
disease, severity, conventional therapy response, nature of triggering events, etc.  
Although the CRSwNP phenotype can be readily determined using endoscopy, it 
is impacted by surgical state and medical therapies and has limited correlation to 
symptom severity. Additionally, there is likely a spectrum of disease from CRSsNP 
with mucosal edema to development of true nasal polyposis that is not accounted 
for using stiff phenotypic classifications.  
However extensive scientific evidence is accumulating evidences that justifies a 
differentiation of sinus disease not only by phenotype (i.e. defined by an 
observable characteristic) but also by recognition of more detailed endotypes (i.e. 
defined by differences in pathogenetic mechanisms that can be discerned by the 
presence of particular biomarker patterns). Indeed CRS was classically divided into 
CRSsNP, intended as a Th1 disorder, and CRSwNP, possibly defined as a Th2 
disorder, but however it has been demonstrated that this paradigm does not apply 
worldwide [Wang X et al., 2016].  
This is why there is a call for further endotyping, based on other patterns, 
including for example TGF-beta expression, Th2 bias and SAg-specific IgE, but 
current data are until now insufficient to propose a full endotypic characterization 
of CRS patients.  
There has been significant progress toward understanding the aetiology and 
pathogenesis of CRS. CRS is still described as multifactorial and there is no clearly 
delineated single molecular pathway that explains the journey from injury to tissue 
change. There is however an emerging consensus that the persistent inflammation 
that defines CRS results from a dysfunctional host-environment interaction 
involving various exogenous agents and changes in the sinonasal mucosa. In 
concert with the definition of CRS as an inflammatory disorder, there has been 
movement away from pathogen-driven hypotheses. This overall concept is in 
agreement with the current understanding of the pathogenesis of chronic mucosal 
inflammatory disorders in general, which describe a balance of interactions 
between the host, commensal flora, potential pathogens and exogenous stresses. 
More original and replication studies are surely needed on this field to corroborate 
these last achievements. 
During last years of biomolecular research mRNA expression of certain specific 
products have been considered an early marker of the cellular modifications and 
have also been used as prognostic indicator for many pathologies [i.e. Geomela et 
al., 2013]; so we wanted and tried to give our contribution to the characterization 
of this disease using the gene expression analysis technique, replicating some of 
the most significant recent studies to strengthen, or not, the evidences of previous 
research findings.  
 
4.1 Difficulties in RNA extraction 
 
Probably because of the high RNAse content of the mucosa of the airways, we 
found major problems in getting good quality RNA from biopsies, often obtaining 
samples with degraded RNA even if it collected and processed with the maximum 
care. Moreover the procedure is quite simple and managed by expert hands both 
in our operating rooms and in our laboratories, where other comparable 
procedure on different tissues usually leads to excellent results. 
For this reason, despite the 85 samples processed, the gene expression analysis has 
been conducted using 13 samples of healthy mucosa (control – C group, total 35 
patients) and 11 samples of hyperplastic/polypoid mucosa (CRSwNP patients – P 
group, total 50 patients), chosen according to the integrity of the RNA in which 
intact 18S and 28S bands were observed.  
Regarding this point is also to notice that, taking separately the initial number of C 
group samples (35) and the one of P group samples (50), the proportion of 
degraded RNA is greater in group P, since only 11/50 specimens were suitable for 
analysis (22%) while 13/35 in C group (about 37%). 
We thought that this low proportion between the specimens taken and those 
suitable for the genetic study could be due to the fact that RNA degrades very 
quickly because of the ribonucleases that are present practically everywhere in the 
mucosa of the airways [Nicolis E et al., 1999]; if the tissue extracted is not 
immediately placed under dry ice, the specimen will quickly become unsuitable for 
RNA analysis. All samples that require longer handling time, such as when mucosa 
is separated from a fragment of bone attached to it, risk deterioration. It is implicit 
that preservation at -80°C requires dry ice or liquid nitrogen being available inside 
the operating room where the biopsies are performed. If these materials are not 
routinely available in an operating room, the time lapsing between sampling and 
preservation, even if it was less than few minutes, might have been longer than 
necessary.   
However in our specimen collection we tried to have maximum care of these 
aspects reducing the time of biopsy till few seconds, so we also suppose that polyp 
tissue is more easily degraded yet because the lower cell density in 
swollen/hyperplastic tissue.  
During the first part of the study, due to the difficulty of extraction on the nasal 
polyps, we considered as an alternative to collect tissue from nasal septum or floor 
of the nasal fossa (usually not involved by polypoid/hyperplastic degeneration, but 
we decided not to proceed to avoid the risk to have biopsy from a wrong, not 
affected, mucosa. So at now we don’t have any realistic solution to improve the 
score of validity of the samples. 
We have not experience with solution to stabilize RNA, such as RNAlater, 
because we used dry ice storage that is considered to be an “ideal” method to 
preserve and store the  RNA samples, available in our case.   
 
4.2 Statistically significant results 
 
Lactoferrin: 
has become a topic of increasing interest in international literature, due to its 
numerous protective anti-bacterial, anti-viral, anti-fungal, anti-tumoural and anti-
inflammatory activities [Zhang Y et al., 2014]. In effect, this latter activity of the 
protein has aroused particular interest in scientific research fields; its implication in 
sinonasal inflammatory disease is a relatively new aspect and opens the way to 
potential new therapeutic perspectives. Some studies highlight the capacity of this 
protein to inhibit fibroblast growth in polyps [Psaltis AJ et al., 2007] and its 
reduction in the tissues of patients with nasal polyposis (our P Group) [Acıoğlu E 
et al., 2012]. Our results seem to strengthen these findings.  
Is known that expression of antimicrobial peptides, such as lactoferrin and 
lysozyme, are part of the innate immune system that appeared dysregulated in 
biofilm-associated CRS [Psaltis AJ et al., 2007; Psaltis AJ et al., 2008; Wang X et 
al., 2014], in which the host’s innate bacteria-clearing mechanisms is impaired, 
facilitating surface attachment and providing more adherence targets in order to 
reach the bacterial quorum required for biofilm formation [Tan L et al., 2010].  
This is another point that could justify the downregulation of Lactoferrin in our 
CRSwNP patients (P group). 
It is interesting to notice how lactoferrin levels in tissues seemed to be not 
influenced by CCS therapy [Acıoğlu E et al., 2012]. In our opinion, this aspect 
actually confirms that there is a possibility of associating topic CCS therapy, which 
is the current gold standard for maintenance treatment of nasal polyps, with one 
based on lactoferrin, and there are also in literature suggestions to dose mucosal 
levels of lactoferrin protein in CRS patients with the intent to provide grounds for 
its possible use in the treatment of nasal polyposis [Psaltis AJ et al., 2007]. 
 
Caveolin 1: 
Damaging of host defense in innate immunity, such as the mechanism of epithelial 
barrier linked to the effectiveness of junction proteins [Hallstranda TS et al., 2014] 
may be involved in CRS pathogenesis [Hamilos DL, 2013] and is also well known 
that primary and acquired immunodeficiencies, determining dysfunction of the 
immune system, may manifest with CRS [Fokkens WJ et al., 2012].  
Epithelial barrier damage may be due in part to the downregulation of junction 
proteins [Coyne CB et al., 2002] through inflammatory mediator release, directly 
via allergen proteolytic activity, or through dysregulation of membrane trafficking 
by downregulation of caveolin-1. This pathogenical mechanism was seen in the 
airway epithelium from asthmatic patients, which share with CRS patients many 
features. 
Moreover Caveolin1 plays a central role in defence against infections and also in 
tumour suppression by reducing the production of Cyclin D1 and endothelial 
nitric oxide synthase. Saying that the significant downregulation of its gene in our 
P Group sounds plausible, and it is in agreement with what literature reports [Lin 
H et al., 2014; Hackett TL, 2013]. 
 
Aquaporine:  
Aquaporine acts as a key tight junction protein in the maintenance of 
mucosalwater homeostasis regulating cellular water transport and cell volume. 
Altered expression of AQPs has been revealed in several types of tumours upon 
their specific tissue localization [Jung HJ et al 2011]. 
Hypothesizing that AQP5 plays a possible role in the pathophysiology of mucosal 
edema, polyp formation and the production of thick secretion that is typical in 
CRSwNP, the down regulation of the gene codifying for AQP5, also reported by 
other Authors, suggest that the treatment of patients with polyps may necessitate 
strategies that target the epithelium, and possibly modulate AQP5, as other 
junction proteins, i.e. cavelolin-1 as expressed above [Frauenfelder C et al., 2014; 
Shikani AH et al. 2013] 
 
Mammaglobin: 
As already explained in the materials and methods chapter, the function of 
mammaglobin is unknown. Since it was found out that mammaglobin is 
overexpressed in breast cancer [Fleming T et al 2000], it began to be investigated 
in the oncological field. Its role in nasal polyps started to be postulated when it 
was discovered that its expression differs in CRSwNP patients compared to the 
healthy ones [Chusakul S et al 2008]. His role remain uncertain, but it is now 
known that other protein of Mammaglobin family are secretory proteins involved 
in the modulation of inflammatory process and can bind steroids [Forsgren B et 
al., 2008; Miele L et al., 1994]. 
As far as its connection with nasal polyposis is quite concerned, certain studies 
have reported results that differ from one to another [Chusakul S et al 2008; Fritz 
SB et al., 2003]. A study demonstrated that mammaglobin is overexpressed in 
nasal polyps, on the grounds of these results, the authors have postulated that 
nasal polyps might show a neoplastic-like growth behaviour [Fritz SB et al., 2003]. 
The results we obtained in our series of samples suggest that mammaglobin A is 
significantly hypo expressed in pathological tissue according to what is reported in 
literature by other authors [Chusakul S et al 2008]. According to these same 
authors, the role that mammaglobin plays in polyposis might lie in its capacity to 
modulate inflammatory response and to bind to CCS. Only further studies will 
discover whether the expression of this protein is actually related to nasal 
polyposis and if it is one of the factors involved in the pathophysiology of this 
disease.  
 
Cox-2: 
In our study a significant decrease of the expression in CRSwNP group (P group). 
This result is agreement with the results of other Authors [Miłoński J et al.,  2015]. 
As these Authors we believe that this result is due to a dysregulation of the 
inflammatory response involving the prostanoid metabolism considered to be a 
possible pathogenic mechanism involved in polyps formation.  
By the way is not clear why Cox-2, normally induced in inflamed tissues, in NP 
results to be downregulated. Pujols L et al stated that COX isozymes appear to 
function coordinately in inflammatory processes and the lack of one COX 
isozyme can be compensated by the other: the variability of COX-1 mRNA in 
nasal polyps may represent the intention of COX-1 to compensate for the 
incapacity of COX-2 to respond to a stressful situation [Pujols L et al.,  2004]. 
Of course this statement seems to be plausible also for our results, even if, in our 
own work we didn’t evaluate Cox-1 gene expression.  
 
4.3 Not statistically significant results 
 
MUC5AC, TGFbeta and hPGDS were examined (Table 6) and showed a 
downregulation of their expression in the NP-CRS respect to the controls, but the 
differences are not statistically significant (p >0.05). For MUC5AC and TGFbeta 
the result was however in accord with literature, not for hPGDS . 
TNF upregulation was not statistically significative, but was in accord with 
literature. 
 
Table 6 – Table of result’s significance  (statistically significant in our results are marked with *) 
related to literature 
 
 
 
 
5 CONCLUSIONS 
Below the clinical observation level of CRS, there likely are several consistent 
pathophysiological mechanisms, different from each other and important in the 
presentation of the underlying inflammation: so we could say that there are 
“inflammatory endotypes” of CRS [Tomassen P et al., 2016]. These endotypes are 
“subtypes of disease defined functionally and pathologically by a molecular 
mechanism”. Each endotype might be identified by specific biomarkers, allowing 
reading the type of mucosal inflammation in nasal biopsies, nasal secretions, or 
better in the serum.  
Biomarker originate from the encoding of specific genes. 
Analysis of gene expression is the first signal of biologic modifications and in the 
last years it’s often reported in association with proteomics. 
In our study we analysed the comparison between the expression of selected genes 
in C Group (control Group, healthy patients) and in P Group (patient affected by 
chronic rhinosinusitis with nasal polyps without hypereosinophilia and/or other 
comorbidities). These candidate genes were selected from literature because of 
their demonstrated/theoretical hyper/hypo-expression at level of pathological 
polypoid tissue.   
From the perspective of researcher, replication studies do not carry the same 
weight as an original piece of work, this mainly because Journals aren’t eager to 
publish such works, not qualified as new researches. But from the perspective of 
contributing to scientific research, replication studies are really very important for 
the continued progress of science. Without validation, future researchers won’t 
know whether to build on the findings of an original work. 
Specifically on this field, concerning CRS, we think that a lot has been done in the 
last years in terms of  trying to validate new theories, but few replication studies 
have been done to validate the original studies. 
In our study most of the analysis we performed on the selected genes confirmed 
the results published in literature.   
In this study for the first time in literature, in the same population many genes 
involved in the pathogenesis of the disease were analysed at the same time (in the 
past these genes were analysed one by one) and we obtained statistically significant 
result in 5 genes out of 9 analysed, and 4 of these corroborate literature results. 
These 5 genes are the ones towards which future researches could address further 
efforts. 
 
Difficulty in mRNA extraction has to be taken into account for future studies, the 
technical problems may be addressed to the quality of the polypoid tissue, poor in 
cells and difficult to be treated. In this scenario the synergy between surgeon and 
laboratory is of great importance and the surgeon must have full knowledge of 
what happen during laboratory processing and what is needed. 
 
In this kind of studies also collaboration between different specialist is of utmost 
importance (i.e. Pneumologist, Allergologist, Immunologist, …) both for patients 
endotyping and in elaborating new treatments, in the perspective of a 
multidisciplinary treatment. 
 
The next steps of our study may consist on the analysis of a Group of patients 
affected also by immunologic associated diseases, Recalcitrant Group (when 
CRSWNP is resistant to treatment, even if considered adequate, it is termed 
‘recalcitrant’), R Group (such as Hypereosinophilia, Asthma,…) comparing them 
to Groups C and P for the selected genes. Also new genes could be selected from 
literature for replication studies or original genes could be tested.  
 
Lactoferrin, which gave us the best results in statistical terms, could be dosed also 
in blood of selected patient to correlate this information to our results and, in 
future, attempts of clinical application of our results could be made. Generally 
allthe significant results given by this kind of studies can lead to further new 
experimental therapies. 
 
Our results, enriching literature, will surely help us in the comprehension of the 
pathogenetic mechanism of CRS and in identifying its specific endotypes. Using 
well-defined endotypes in clinical studies might in fact allow to identify patient 
groups that best benefit from existing as well as new treatments [Bachert C et al., 
2016] and this could result in personalized treatments and in a substantial 
improvement in future patient care. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 ABBREVIATION 
 
AERD: aspirin exacerbated respiratory disease 
AOAH: acyloxyacyl gene 
APC: antigen-presenting cell 
ASA: acetylsalicylic acid 
BAFF: B-cell activating factor of the TNF family 
CF: cystic fibrosis 
CFTR: cystic fibrosis transmembrane conductance regulator 
COX: cyclooxygenase 
CRS: chronic rhinosinusitis 
CRSsNP: chronic rhinosinusitis without nasal polyps 
CRSwNP: chronic rhinosinusitis with nasal polyps 
DC: dendritic cell 
DNA: desoxyribonucleic acid 
ECM: extracellular matrix 
FESS: functional endoscopic sinus surgery 
GWAS: genome-wide association study 
HLA: human leukocyte antigen 
IBD: inflammatory bowel disease 
IFN-γ: interferon gamma 
Ig: immunoglobulin  
IL: interleukin 
LAMA2: laminin alfa 2 
LAMB1: laminin beta 1 
MCC: mucociliary clearance 
MET: met proto-oncogene 
MMP: metalloproteinase 
mRNA: messenger ribonucleic acid 
NLR: NOD-like receptor 
NOD: nucleotide-binding oligomerization domain 
NP: nasal polyp 
NSAID: non-steroidal anti-inflammatory drug 
OR: odd ratio 
PAI: plasminogen activator inhibitor 
PAMP: pathogen-associated molecular pattern 
PAR: protease activated receptor 
PCR: polymerase chain reaction  
PGE: prostaglandin 
pGWAS: pooling-based genome-wide association study 
PRR: pattern recognition receptor 
qPCR: quantitative PCR 
RT PCR: reverse transcription PCR 
S100: calcium binding protein  
SAg: superantigen 
SERPINA: alfa 1 antitripsina 
SNP: single nucleotide polymorphism 
SPINK5: serine protease inhibitor Kazal-type 5 
STAT3: signal transducer and activator of transcription 3 
TGF-β R: transforming growth factor beta receptor 
TGF-β: transforming growth factor beta 
Th: T helper lymphocyte 
Th1: T helper 1 lymphocyte 
Th17: T helper 17 lymphocyte 
Th2: T helper 2 lymphocyte 
TIMP: tissue inhibitor of metalloproteinase 
TLR: toll-like receptor 
TNF: tumor necrosis factor 
Treg: rugulatory T cell 
uPA: urokinase plasminogen activator 
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